Titre : Tumeurs trophoblastiques

Tumeurs trophoblastiques : Questions médicales fréquentes

Termes MeSH sélectionnés :

MicroRNAs
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tumeurs trophoblastiques : Questions médicales les plus fréquentes", "headline": "Tumeurs trophoblastiques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tumeurs trophoblastiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-12", "dateModified": "2025-03-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tumeurs trophoblastiques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Complications tumorales de la grossesse", "url": "https://questionsmedicales.fr/mesh/D011252", "about": { "@type": "MedicalCondition", "name": "Complications tumorales de la grossesse", "code": { "@type": "MedicalCode", "code": "D011252", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Choriocarcinome", "alternateName": "Choriocarcinoma", "url": "https://questionsmedicales.fr/mesh/D002822", "about": { "@type": "MedicalCondition", "name": "Choriocarcinome", "code": { "@type": "MedicalCode", "code": "D002822", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.208" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Choriocarcinome non gestationnel", "alternateName": "Choriocarcinoma, Non-gestational", "url": "https://questionsmedicales.fr/mesh/D031954", "about": { "@type": "MedicalCondition", "name": "Choriocarcinome non gestationnel", "code": { "@type": "MedicalCode", "code": "D031954", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.208.438" } } }, { "@type": "MedicalWebPage", "name": "Tumeur trophoblastique du site d'implantation placentaire", "alternateName": "Trophoblastic Tumor, Placental Site", "url": "https://questionsmedicales.fr/mesh/D018245", "about": { "@type": "MedicalCondition", "name": "Tumeur trophoblastique du site d'implantation placentaire", "code": { "@type": "MedicalCode", "code": "D018245", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.208.875" } } } ] }, { "@type": "MedicalWebPage", "name": "Maladie trophoblastique gestationnelle", "alternateName": "Gestational Trophoblastic Disease", "url": "https://questionsmedicales.fr/mesh/D031901", "about": { "@type": "MedicalCondition", "name": "Maladie trophoblastique gestationnelle", "code": { "@type": "MedicalCode", "code": "D031901", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.416" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Môle hydatiforme", "alternateName": "Hydatidiform Mole", "url": "https://questionsmedicales.fr/mesh/D006828", "about": { "@type": "MedicalCondition", "name": "Môle hydatiforme", "code": { "@type": "MedicalCode", "code": "D006828", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.416.875" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Môle invasive", "alternateName": "Hydatidiform Mole, Invasive", "url": "https://questionsmedicales.fr/mesh/D002820", "about": { "@type": "MedicalCondition", "name": "Môle invasive", "code": { "@type": "MedicalCode", "code": "D002820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.416.875.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Môle invasive", "alternateName": "Hydatidiform Mole, Invasive", "url": "https://questionsmedicales.fr/mesh/D002820", "about": { "@type": "MedicalCondition", "name": "Môle invasive", "code": { "@type": "MedicalCode", "code": "D002820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C12.050.703.720.949.416.875.500" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Tumeurs trophoblastiques", "alternateName": "Trophoblastic Neoplasms", "code": { "@type": "MedicalCode", "code": "D014328", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Maryam Shahi", "url": "https://questionsmedicales.fr/author/Maryam%20Shahi", "affiliation": { "@type": "Organization", "name": "Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA. Shahi.Maryam@mayo.edu." } }, { "@type": "Person", "name": "Wendy Allen-Rhoades", "url": "https://questionsmedicales.fr/author/Wendy%20Allen-Rhoades", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Mayo Clinic, Rochester, MN, USA." } }, { "@type": "Person", "name": "Michael B Ishitani", "url": "https://questionsmedicales.fr/author/Michael%20B%20Ishitani", "affiliation": { "@type": "Organization", "name": "Department of Pediatric Surgery, Mayo Clinic, Rochester, MN, USA." } }, { "@type": "Person", "name": "Kevin M Elias", "url": "https://questionsmedicales.fr/author/Kevin%20M%20Elias", "affiliation": { "@type": "Organization", "name": "Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA; New England Trophoblastic Disease Center, Dana-Farber Cancer Institute, MA, USA." } }, { "@type": "Person", "name": "Ross S Berkowitz", "url": "https://questionsmedicales.fr/author/Ross%20S%20Berkowitz", "affiliation": { "@type": "Organization", "name": "Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA; New England Trophoblastic Disease Center, Dana-Farber Cancer Institute, MA, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "MicroRNA-resistant alleles of", "datePublished": "2022-05-11", "url": "https://questionsmedicales.fr/article/35544571", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1126/sciadv.abn5907" } }, { "@type": "ScholarlyArticle", "name": "The role of microRNAs in carcinogenesis and the utility of microRNA determination in diagnosis of gastric cancer development.", "datePublished": "2023-04-17", "url": "https://questionsmedicales.fr/article/37087560", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.26402/jpp.2022.6.01" } }, { "@type": "ScholarlyArticle", "name": "MicroRNA and MicroRNA-Target Variants Associated with Autism Spectrum Disorder and Related Disorders.", "datePublished": "2022-07-26", "url": "https://questionsmedicales.fr/article/35893067", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes13081329" } }, { "@type": "ScholarlyArticle", "name": "Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.", "datePublished": "2024-06-01", "url": "https://questionsmedicales.fr/article/38918674", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.31557/APJCP.2024.25.6.2113" } }, { "@type": "ScholarlyArticle", "name": "Exosomal microRNA‑4516, microRNA‑203 and SFRP1 are potential biomarkers of acute myocardial infarction.", "datePublished": "2023-05-19", "url": "https://questionsmedicales.fr/article/37203392", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3892/mmr.2023.13010" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies urogénitales", "item": "https://questionsmedicales.fr/mesh/D000091642" }, { "@type": "ListItem", "position": 3, "name": "Maladies de l'appareil urogénital féminin et complications de la grossesse", "item": "https://questionsmedicales.fr/mesh/D005261" }, { "@type": "ListItem", "position": 4, "name": "Complications de la grossesse", "item": "https://questionsmedicales.fr/mesh/D011248" }, { "@type": "ListItem", "position": 5, "name": "Complications tumorales de la grossesse", "item": "https://questionsmedicales.fr/mesh/D011252" }, { "@type": "ListItem", "position": 6, "name": "Tumeurs trophoblastiques", "item": "https://questionsmedicales.fr/mesh/D014328" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tumeurs trophoblastiques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tumeurs trophoblastiques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tumeurs trophoblastiques", "description": "Comment diagnostique-t-on une tumeur trophoblastique ?\nQuels marqueurs tumoraux sont utilisés ?\nLes échographies sont-elles utiles ?\nQuand faut-il suspecter une tumeur trophoblastique ?\nPeut-on utiliser l'IRM pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=MicroRNAs&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tumeurs trophoblastiques", "description": "Quels sont les symptômes courants ?\nLes tumeurs trophoblastiques causent-elles des douleurs ?\nY a-t-il des symptômes systémiques ?\nLes nausées sont-elles fréquentes ?\nPeut-on avoir des symptômes sans grossesse récente ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=MicroRNAs&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tumeurs trophoblastiques", "description": "Peut-on prévenir les tumeurs trophoblastiques ?\nLe suivi après une grossesse est-il important ?\nLes antécédents familiaux influencent-ils le risque ?\nLes femmes ayant eu des grossesses multiples sont-elles à risque ?\nY a-t-il des recommandations pour les femmes enceintes ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=MicroRNAs&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tumeurs trophoblastiques", "description": "Quels traitements sont disponibles ?\nLa chimiothérapie est-elle efficace ?\nQuand la chirurgie est-elle nécessaire ?\nY a-t-il des effets secondaires des traitements ?\nLa radiothérapie est-elle utilisée ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=MicroRNAs&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tumeurs trophoblastiques", "description": "Quelles complications peuvent survenir ?\nLes tumeurs trophoblastiques peuvent-elles être mortelles ?\nComment les métastases se manifestent-elles ?\nLes complications affectent-elles la fertilité ?\nY a-t-il des risques psychologiques associés ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=MicroRNAs&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tumeurs trophoblastiques", "description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle ?\nLes antécédents médicaux influencent-ils le risque ?\nLes habitudes de vie affectent-elles le risque ?\nLes facteurs environnementaux sont-ils impliqués ?", "url": "https://questionsmedicales.fr/mesh/D014328?mesh_terms=MicroRNAs&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une tumeur trophoblastique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins, échographies et biopsies." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de l'hormone chorionique gonadotrope (hCG) sont souvent mesurés." } }, { "@type": "Question", "name": "Les échographies sont-elles utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles permettent de visualiser les masses et d'évaluer leur taille." } }, { "@type": "Question", "name": "Quand faut-il suspecter une tumeur trophoblastique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Après une grossesse, si des symptômes anormaux ou des niveaux d'hCG élevés persistent." } }, { "@type": "Question", "name": "Peut-on utiliser l'IRM pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM peut être utilisée pour évaluer l'extension des tumeurs dans certains cas." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des saignements vaginaux, douleurs abdominales et nausées." } }, { "@type": "Question", "name": "Les tumeurs trophoblastiques causent-elles des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs abdominales peuvent survenir en raison de la pression exercée." } }, { "@type": "Question", "name": "Y a-t-il des symptômes systémiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, la fièvre et la perte de poids peuvent apparaître." } }, { "@type": "Question", "name": "Les nausées sont-elles fréquentes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les nausées peuvent être fréquentes, surtout en cas de tumeur avancée." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans grossesse récente ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes peuvent apparaître même sans grossesse récente, nécessitant une évaluation." } }, { "@type": "Question", "name": "Peut-on prévenir les tumeurs trophoblastiques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical est conseillé." } }, { "@type": "Question", "name": "Le suivi après une grossesse est-il important ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier peut aider à détecter précocement des anomalies." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de tumeurs trophoblastiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les femmes ayant eu des grossesses multiples sont-elles à risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les grossesses multiples peuvent augmenter le risque de tumeurs trophoblastiques." } }, { "@type": "Question", "name": "Y a-t-il des recommandations pour les femmes enceintes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi prénatal régulier est recommandé pour surveiller la santé maternelle et fœtale." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et la surveillance." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la chimiothérapie est souvent efficace pour traiter les tumeurs trophoblastiques." } }, { "@type": "Question", "name": "Quand la chirurgie est-elle nécessaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est nécessaire si la tumeur est localisée et accessible." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme la fatigue, les nausées et la perte de cheveux peuvent survenir." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La radiothérapie est rarement utilisée, sauf dans des cas spécifiques de métastases." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des saignements, des infections et des métastases." } }, { "@type": "Question", "name": "Les tumeurs trophoblastiques peuvent-elles être mortelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, si elles ne sont pas traitées, elles peuvent entraîner des complications graves." } }, { "@type": "Question", "name": "Comment les métastases se manifestent-elles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases peuvent affecter les poumons, le foie et d'autres organes, causant divers symptômes." } }, { "@type": "Question", "name": "Les complications affectent-elles la fertilité ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines complications peuvent affecter la fertilité future des femmes." } }, { "@type": "Question", "name": "Y a-t-il des risques psychologiques associés ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diagnostic et le traitement peuvent entraîner des troubles psychologiques chez les patientes." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de grossesse molaires, les grossesses multiples et l'âge maternel avancé." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les femmes de plus de 35 ans ont un risque accru de développer des tumeurs trophoblastiques." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de tumeurs trophoblastiques augmentent le risque de récidive." } }, { "@type": "Question", "name": "Les habitudes de vie affectent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes, comme le tabagisme, peuvent influencer le risque de complications." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils impliqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs environnementaux peuvent également jouer un rôle dans le développement de ces tumeurs." } } ] } ] }

Sources (10000 au total)

Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.

The lack of indicators to measure tumor's invasive biological behavior is an important issue. The aim of this study was to examine the effect of miRNAs 129 and 145 on tumor progression as well as pati... Seventy five breast cancer (BC) patients and 75 controls were included in this research. Two miRNA expressions were estimated using real-time PCR. Biomarkers for BC detection was tested using ROC curv... miR-129 and miR-145 expressions were significant. miR-129 and miR-145 classifiers (AUC = 0.943 and 0.748, respectively) help diagnose BC. Unlike miR-145, miR-129 did not affect the Kaplan-Meier surviv... The miRNA signature can help detect survival-associated miRNAs and develop BC miRNA therapeutics....

Tissue and Circulating MicroRNA-31, MicroRNA-200b, and MicroRNA-200c Reflects Disease Activity in Crohn's Disease Patients: Results from the BIOMIR Study.

MicroRNAs (miR) have altered expression in multiple autoimmune disorders including inflammatory bowel disease. The aim of the study was to assess the tissue and circulating miR-31, miR-200b, and miR-2... The study included 45 patients with histopathological confirmed CD and active disease (defined as fecal calprotectin >50 μg/g and Simple Endoscopic Score (SES) of CD >3), and 21 subjects as controls f... Mean fecal calprotectin was 1540±890 μg/g. Mean SES-CD was 8.9±4.2. Tissue and circulating miR- 31 were significantly correlated with fecal calprotectin (r=0.81, r=0.83, p<0.01) and with SES-CD (r=0.8... Tissue and circulating miR-31, miR-200b, and miR-200c reflect disease activity in CD patients and can be used as biomarkers for active disease....

Circulating metals, leukocyte microRNAs and microRNA networks: A profiling and functional analysis in Chinese adults.

Metals in the human body represent both environmental exposure and nutritional status. Little is known about the miRNA signature in relation to circulating metals in humans.... To characterize metal-associated miRNAs in leukocytes, individually and collectively as networks.... In a panel of 160 Chinese adults, we measured 23 metals/metalloids in plasma, and sequenced miRNAs and mRNAs in leukocytes. We used linear regression to model the associations between ln-transformed m... We identified 55 metal-associated miRNAs at false discovery rate-adjusted P < 0.05. In particular, we found that lead, nickel, and vanadium were positively associated with potentially lymphocyte-enric... At commonly exposed low levels, circulating metals were associated with distinct miRNA signatures in leukocytes. The identified miRNAs, individually or as regulatory networks, may provide a mechanisti...